John Overdeck’s PDL BioPharma, Inc. PDLI Stock Holding History

John Overdeck’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-49,093	Closed	-$106K	–	4200
2019 Q3	$106K	Sell	49,093 -312,588	-86%	-$835K	﹤0.01%	3301
2019 Q2	$1.14M	Sell	361,681 -224,467	-38%	-$728K	﹤0.01%	1850
2019 Q1	$2.18M	Sell	586,148 -11,716	-2%	-$39.6K	0.01%	1368
2018 Q4	$1.73M	Buy	597,864 +211,036	+55%	+$580K	0.01%	1317
2018 Q3	$1.02M	Buy	386,828 +212,225	+122%	+$521K	﹤0.01%	1972
2018 Q2	$409K	Sell	174,603 -313,386	-64%	-$875K	﹤0.01%	2759
2018 Q1	$1.44M	Sell	487,989 -387,492	-44%	-$1.06M	﹤0.01%	1762
2017 Q4	$2.4M	Sell	875,481 -294,718	-25%	-$905K	0.01%	1341
2017 Q3	$3.97M	Buy	1,170,199 +389,183	+50%	+$1.08M	0.01%	912
2017 Q2	$1.93M	Buy	781,016 +128,856	+20%	+$296K	0.01%	1445
2017 Q1	$1.48M	Sell	652,160 -221,548	-25%	-$490K	0.01%	1645
2016 Q4	$1.85M	Sell	873,708 -70,494	-7%	-$197K	0.01%	1548
2016 Q3	$3.16M	Sell	944,202 -179,691	-16%	-$570K	0.01%	1163
2016 Q2	$3.53M	Sell	1,123,893 -278,179	-20%	-$928K	0.02%	941
2016 Q1	$4.67M	Sell	1,402,072 -524,990	-27%	-$1.64M	0.02%	746
2015 Q4	$6.82M	Buy	1,927,062 +1,162,493	+152%	+$4.87M	0.03%	558
2015 Q3	$3.85M	Sell	764,569 -979,001	-56%	-$5.61M	0.02%	599
2015 Q2	$11.2M	Sell	1,743,570 -179,823	-9%	-$1.2M	0.05%	412
2015 Q1	$13.5M	Buy	1,923,393 +1,856,872	+2,791%	+$13.4M	0.06%	376
2014 Q4	$513K	Sell	66,521 -164,479	-71%	-$1.3M	﹤0.01%	1714
2014 Q3	$1.73M	Sell	231,000 -5,319	-2%	-$49.4K	0.01%	910
2014 Q2	$2.29M	Sell	236,319 -1,340,638	-85%	-$11.9M	0.01%	974
2014 Q1	$13.1M	Buy	1,576,957 +1,162,472	+280%	+$9.96M	0.07%	373
2013 Q4	$3.5M	Sell	414,485 -926,000	-69%	-$7.8M	0.02%	759
2013 Q3	$10.7M	Buy	1,340,485 +150,682	+13%	+$1.21M	0.07%	341
2013 Q2	$9.19M	Buy	+1,189,803	New	+$9.28M	0.06%	366

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's PDLI Position: Q4 2019 in Review

John Overdeck sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 49,093 shares — an estimated $106K sold.

John Overdeck first reported a position in PDLI in Q2 2013 and held it in 26 quarters. The position peaked at $13.5M in Q1 2015. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

John Overdeck reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
John Overdeck sold 49,093 PDL BioPharma, Inc. shares in Q4 2019, an estimated $106K.
John Overdeck first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 26 quarters.
John Overdeck's PDL BioPharma, Inc. position peaked at $13.5M in Q1 2015.
150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on Two Sigma Investments's 13F filing for Q4 2019, filed 14 Feb 2020.